The promise of virally vectored DNA and mRNA vaccines is tremendous in terms of vaccine safety and speed of response to new pathogens. This article explores why these approaches have attracted attention in light of the COVID-19 pandemic and why they are highly appropriate for rapid vaccine development and deployment.
List view / Grid view
Centre for Process Innovation (CPI)
Filter the results
13 October 2015 | By Victoria White
CPI and Arecor carried out the investigation with the hope of improving stability and shelf life throughout transportation and storage...